Tag: preclinical research

Preclinical Data Showing Synergy of Biothera Pharmaceuticals’ Imprime PGG and a CD40 Agonist in a Pancreatic Cancer Model Presented at Keystone Symposia

EAGAN, MN — March 26, 2018 — Biothera Pharmaceuticals, Inc. and the Abramson Cancer Center of the University of Pennsylvania announced today the presentation of new preclinical data demonstrating the combination of Imprime PGG and a CD40 agonist antibody stimulated T cell-dependent anti-tumor activity in a pancreatic cancer model.  The data were presented at the ongoing Keystone Symposia Conference – Cancer Immunotherapy: Combinations in Montreal,...

Read More


Biothera Pharmaceuticals Presents Data Broadening Imprime PGG Mechanism of Action

Reduces expression of IDO, a potent suppressor of an anti-cancer T cell response Supplementation with IVIG boosts biomarker levels, restoring Imprime-driven pharmacodynamic responses EAGAN, MN — November 13, 2017 — Biothera Pharmaceuticals, Inc. announced today the presentation of clinical and preclinical research supporting the mechanism of action for the Company’s cancer immunotherapy Imprime PGG, which is currently being evaluated in combination with immune checkpoint inhibitor...

Read More


Biothera Pharmaceuticals Presents Preclinical Data Showing Imprime PGG Activates Natural Killer Cell-Mediated Tumor Killing

Data Presented at AACR-NCI-EORTC International Conference EAGAN, MN — October 30, 2017 — Biothera Pharmaceuticals, Inc. announced today the presentation of new preclinical findings showing that the Company’s Phase 2 cancer immunotherapy Imprime PGG activates Natural Killer (NK) cell-mediated killing of cancer cells. The data were presented at the ongoing AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, taking...

Read More


Biothera Pharmaceuticals Announces Data Demonstrating Unique Immune Response Profile Generated by Phase 2 Cancer Immunotherapy Imprime PGG

Researchers to Present Preclinical Data at EORTC-NCI-AACR Symposium EAGAN, MN — November 29, 2016 — Biothera Pharmaceuticals, Inc. will present data tomorrow illustrating the unique cytokine response generated by its phase 2 cancer immunotherapy Imprime PGG, the only Pathogen Associated Molecular Patterning (PAMP) molecule that has been successfully administered systemically. The data will be highlighted in two poster presentations at the 28th EORTC-NCI-AACR Symposium on Molecular...

Read More


Biothera Pharmaceuticals Preclinical Data Further Validate Mechanism of its Phase 2 Cancer Immunotherapy, Imprime PGG

3 Poster Presentations Scheduled for Society for Immunotherapy of Cancer Annual Meeting EAGAN, MN — November 11, 2016 — Biothera Pharmaceuticals, Inc. will present new preclinical data today that further validate the ability of its Phase 2 cancer immunotherapy drug Imprime PGG to induce coordinated innate and adaptive immune responses that may enhance the efficacy of checkpoint inhibitor therapies. The data will be highlighted in three...

Read More


Preclinical Data Published in PLOS ONE Support Use of a Patient Selection Biomarker for Biothera Pharmaceuticals’ Phase 2 Cancer Immunotherapy Imprime PGG

Formation of Imprime PGG-Immune Complex Essential to Anti-Tumor Activity EAGAN, MN — November 7, 2016 — Biothera Pharmaceuticals, Inc. today announced the publication of preclinical research identifying an essential mechanism in the activation of anti-cancer immune responses by Imprime PGG, the Company’s Phase 2 cancer immunotherapy drug. The formation of an immune complex between Imprime PGG and endogenous anti-beta glucan antibodies (ABA) offers the potential...

Read More